Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
1997
564
LTM Revenue $8.7M
LTM EBITDA -$543M
$5.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cytokinetics has a last 12-month revenue of $8.7M and a last 12-month EBITDA of -$543M.
In the most recent fiscal year, Cytokinetics achieved revenue of $7.5M and an EBITDA of -$457M.
Cytokinetics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Cytokinetics valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $94.6M | $7.5M | $3.2M | $8.7M | XXX |
Gross Profit | -$89.5M | -$146M | -$323M | XXX | XXX |
Gross Margin | -95% | -1942% | -10070% | XXX | XXX |
EBITDA | -$332M | -$457M | -$534M | -$543M | XXX |
EBITDA Margin | -351% | -6065% | -16667% | -6244% | XXX |
Net Profit | -$215M | -$389M | -$526M | XXX | XXX |
Net Margin | -228% | -5165% | -16427% | XXX | XXX |
Net Debt | $30.2M | $544M | $504M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 14, 2025, Cytokinetics's stock price is $46.
Cytokinetics has current market cap of $5.4B, and EV of $5.2B.
See Cytokinetics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$5.2B | $5.4B | XXX | XXX | XXX | XXX | $-5.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 14, 2025, Cytokinetics has market cap of $5.4B and EV of $5.2B.
Cytokinetics's trades at 600.9x LTM EV/Revenue multiple, and -9.6x LTM EBITDA.
Analysts estimate Cytokinetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cytokinetics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $5.2B | XXX | XXX | XXX |
EV/Revenue | 1631.2x | XXX | XXX | XXX |
EV/EBITDA | -9.8x | XXX | XXX | XXX |
P/E | -9.5x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -18.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCytokinetics's NTM/LTM revenue growth is 748%
Cytokinetics's revenue per employee for the last fiscal year averaged $13K, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Cytokinetics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cytokinetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cytokinetics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | -57% | XXX | XXX | XXX | XXX |
EBITDA Margin | -16667% | XXX | XXX | XXX | XXX |
EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -15919% | XXX | XXX | XXX | XXX |
Revenue per Employee | $13K | XXX | XXX | XXX | XXX |
Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 2306% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 2306% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cytokinetics acquired XXX companies to date.
Last acquisition by Cytokinetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cytokinetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Cytokinetics founded? | Cytokinetics was founded in 1997. |
Where is Cytokinetics headquartered? | Cytokinetics is headquartered in United States of America. |
How many employees does Cytokinetics have? | As of today, Cytokinetics has 564 employees. |
Who is the CEO of Cytokinetics? | Cytokinetics's CEO is Mr. Robert I. Blum. |
Is Cytokinetics publicy listed? | Yes, Cytokinetics is a public company listed on NAS. |
What is the stock symbol of Cytokinetics? | Cytokinetics trades under CYTK ticker. |
When did Cytokinetics go public? | Cytokinetics went public in 2004. |
Who are competitors of Cytokinetics? | Similar companies to Cytokinetics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Cytokinetics? | Cytokinetics's current market cap is $5.4B |
What is the current revenue of Cytokinetics? | Cytokinetics's last 12-month revenue is $8.7M. |
What is the current EBITDA of Cytokinetics? | Cytokinetics's last 12-month EBITDA is -$543M. |
What is the current EV/Revenue multiple of Cytokinetics? | Current revenue multiple of Cytokinetics is 600.9x. |
What is the current EV/EBITDA multiple of Cytokinetics? | Current EBITDA multiple of Cytokinetics is -9.6x. |
What is the current revenue growth of Cytokinetics? | Cytokinetics revenue growth between 2023 and 2024 was -57%. |
Is Cytokinetics profitable? | Yes, Cytokinetics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.